A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance
Open Access
- 1 December 2019
- journal article
- research article
- Published by Elsevier in Genes & Diseases
- Vol. 6 (4) , 419-430
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- American Cancer Society (RSG-15-009-01-CDD)
- National Cancer Institute (R01 CA186662, R01CA214019)
- National Natural Science Foundation of China (81272389, 81472674, 81502486)
This publication has 33 references indexed in Scilit:
- The MDM2-p53 pathway revisitedJournal of Biomedical Research, 2013
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinomaJournal of Translational Medicine, 2009
- Murine double minute 2: p53-independent roads lead to genome instability or deathTrends in Biochemical Sciences, 2009
- Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibitionProceedings of the National Academy of Sciences, 2008
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004
- In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 2004
- Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53Journal of Biological Chemistry, 2000
- Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.Genes & Development, 1994